Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Kedem Pharmaceuticals
Kedem Pharmaceuticals
Activities:
Drug Delivery
Research & Development
Cardiovascular
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Scleroderma treatment by Certa Therapeutics granted US FDA fast track
FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
Naobios and Sumagen sign exclusive partnership to develop HIV vaccine
Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Rapid increase in purchasing teams expected at CPHI North America
Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Bio-Rad and Oncocyte partner to commercialise transplant monitoring with Droplet Digital PCR
The collaboration aims to provide researchers with tools to enable transformational monitoring of key biomarkers in solid tissue transplants
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Drug Delivery
Kedem Pharmaceuticals appoints new chief operating officer
Drug delivery systems specialist promotes Dr Lola Maksumova
Drug Delivery
Kedem Pharmaceuticals initiates development of sublingual cancer drug
Gleevec is for the treatment of several blood related cancers
Subscribe now